Connect with us


Algernon Pharmaceuticals completes final dosing in DMT study for stroke and TBI treatment

AGN Neuro plans to publish the data from the study in an upcoming issue of a peer-reviewed paper
The post Algernon Pharmaceuticals completes final dosing…



This article was originally published by Mugglehead

Algernon Pharmaceuticals Inc.’s (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) subsidiary Algernon Neuroscience will be the first company to test intravenous (IV) DMT on people suffering from traumatic brain injury or stroke.

On Monday, the clinical-stage pharmaceutical development company announced the successful completion of dosing in the final cohort of its Phase 1 clinical study involving AP-188 which is DMT.

AGN Neuro is the first company to test DMT at single escalating concentrations with an IV dose for a 6-hour duration. The safety review committee has confirmed no safety or tolerability issues with the highest dose.

This dose maintained plasma DMT concentrations at targeted levels and was below the established psychedelic dose.

The psychedelic dose of DMT was previously identified as 0.2 mg/kg by Dr. Rick Strassman, a DMT researcher and Algernon consultant, in his pioneering DMT human studies in the early 1990s.

DMT is believed to activate pathways involved in forming neuronal connections and has been shown to increase the number of dendritic spines on cortical neurons. These spines form synapses with other neurons and are a critical site for neuronal transmission.

The Phase 1 trial was conducted at the Centre for Human Drug Research in Leiden, Netherlands. It aimed to identify the safety, tolerability and pharmacokinetics of sub-psychedelic doses of DMT when administered as an intravenous bolus followed by a prolonged infusion of 6 hours.

AGN Neuro plans to publish the data from the study in an upcoming issue of a peer-reviewed paper.

“Neuroplasticity’s role in healing the brain after an injury is one of the most exciting areas of research globally in the pursuit of a treatment for stroke and TBI, and AGN Neuro is at the forefront of this work,” Algernon CEO Christopher J. Moreau said.

Read more: Algernon partners with Yale University for phase II DMT study

Read more: Small Pharma gets approval for upcoming injectable DMT trial on humans

Photo by Terpsichore via Wikimedia Commons.

DMT assists in brain recovery post-injury

N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.

DMT occurs naturally in many plant species and animals, including humans, and has been used in religious ceremonies as a traditional spiritual medicine by Indigenous people in the Amazon basin.

The molecule acts on various receptors, such as serotonin receptors and the multi-functional sigma-1 receptor. The sigma-1 receptor responds to stress and supports cell survival, neuroprotection, neuroplasticity and neuroimmunomodulation. Additionally, DMT stimulates the release of Brain-Derived Neurotrophic Factor (BDNF), a protein that assists in brain recovery post-injury.

Algernon has submitted patent applications for DMT pamoate and nicotinate, which are innovative salt forms of DMT. These applications extend to the formulation, dosage and usage for ischemic stroke and TBI. The company has also proposed patents for a combined therapy approach involving DMT and stroke rehabilitation, specifically Constraint Induced Movement Therapy.

Algernon announced last October it entered into a clinical trials agreement with Yale University to supply cGMP DMT to a study looking into DMT as a treatment for depression.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

The post Algernon Pharmaceuticals completes final dosing in DMT study for stroke and TBI treatment appeared first on Mugglehead Magazine.




Life Sciences

Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder

–Topline efficacy data expected in Q4 2023 – – Preparations are underway to scale the CYB003 program to a potential Phase 3 study in early 2024 –…

Continue Reading

Atai, Cybin Give Positive Psychedelic Drug Study Updates

The two companies also shared next steps in their drug testing regimens.
The post Atai, Cybin Give Positive Psychedelic Drug Study Updates appeared first…

Continue Reading
Life Sciences

atai Life Sciences Completes Phase 1 Study of Oral DMT

Atai Life Sciences has completed its Phase 1 study of VLS-01, an oral DMT for treatment-resistant depression (TRD).
The post atai Life Sciences Completes…

Continue Reading